Skip to content

Time-restricted Eating and High-intensity Interval Training for Metabolic Health in Adults With Overweight/Obesity

Time-restricted Eating and High-intensity Interval Training for Long-term Improvement in Metabolic Health

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07036562
Acronym
TREHIIT-3
Enrollment
100
Registered
2025-06-25
Start date
2025-09-11
Completion date
2027-07-01
Last updated
2026-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and Obesity

Keywords

time-restricted eating, high-intensity interval training, exercise, diet, metabolic health, lifestyle intervention

Brief summary

This study will investigate the effects of 12 months periodised time-restricted eating combined with high-intensity interval training compared with a control group on fat mass in adults with overweight/obesity. Participants in the intervention group will complete the intervention remotely and will receive follow-up by telephone. Before randomisation, after 6 months and after 12 months, the investigators will measure the participants' body composition, physical fitness, fasting blood glucose and insulin, blood lipids, and blood pressure. Physical activity, diet, sleep quality, appetite, and adherence to the intervention will also be measured. Secondary sub-analyses of sex differences in the responses to the intervention will be performed.

Interventions

1-month intense periods of maximal daily eating window of 10 hours and high-intensity interval training (three weekly, unsupervised, aerobic exercise sessions performed at \> 90 % heart rate maximum), separated by 3-month maintenance periods of time-restricted eating on 5 days per week and minimum 1 HIIT session per week. Each exercise session will last for 33-38 minutes. Participants will receive digital follow-up once weekly during intense periods, and once monthly during maintenance periods. The intervention period will be 12 months in total.

Sponsors

Norwegian University of Science and Technology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Body mass index ≥ 27 kg/m² * Able to walk or ride a bike \> 60 min

Exclusion criteria

* On-going pregnancy * Lactation within 24 weeks of study commencement * High-intensity exercise ≥ 1/week * Habitual eating window ≤12 hours/day * Taking hypertension, glucose-, or lipid-lowering drugs * Body mass variation ≥ 4 kg three months prior to study commencement * Known diabetes mellitus (type 1 or 2) or cardiovascular disease * Working night shifts

Design outcomes

Primary

MeasureTime frameDescription
Total fat massFrom baseline to after 12 monthsChange in total fat mass measured with bioelectrical impedance analysis

Secondary

MeasureTime frameDescription
Blood glucoseFrom baseline to after 6 months and after 12 monthsFasting concentration of plasma glucose
Total fat massFrom baseline to after 6 monthsChange in total fat mass measured with bioelectrical impedance analysis
InsulinFrom baseline to after 6 months and after 12 monthsFasting concentration of plasma insulin C-peptide
Average glucose levelsFrom baseline to after 6 months and after 12 monthsGlycated haemoglobin (HbA1c)
Blood cholesterolFrom baseline to after 6 months and after 12 monthsTotal fasting cholesterol in blood
LDL-cholesterolFrom baseline to after 6 months and after 12 monthsFasting low-density lipoprotein-cholesterol in blood
HDL-cholesterolFrom baseline to after 6 months and after 12 monthsFasting high-density lipoprotein-cholesterol in blood
TriglyceridesFrom baseline to after 6 months and after 12 monthsFasting triglycerides in blood
Cardiorespiratory fitnessFrom baseline to after 6 months and after 12 monthsPeak oxygen uptake at a maximum effort test, measured in mL/min/kg and L/min
Insulin sensitivityFrom baseline to after 6 months and after 12 monthsHomeostatic model assessment for insulin resistance (HOMA-IR): 1.5 + fasting plasma glucose (mmol/L) x fasting plasma insulin C-peptide (pmol/L)/2800
Body massFrom baseline to after 6 months and after 12 monthsIn kg, estimated with bioelectrical impedance analysis
Fat-free massFrom baseline to after 6 months and after 12 monthsIn kg, estimated with bioelectrical impedance analysis
Visceral fat areaFrom baseline to after 6 months and after 12 monthsIn cm2, estimated with bioelectrical impedance analysis
Systolic blood pressureFrom baseline to after 6 months and after 12 monthsAverage of three measurements during rest in seated position, in mmHg
Diastolic blood pressureFrom baseline to after 6 months and after 12 monthsAverage of three measurements during rest in seated position, in mmHg
Resting heart rateFrom baseline to after 6 months and after 12 monthsAverage of three measurements during rest in sitting position, in beats/min
Physical activity levelsFrom baseline to after 6 months and after 12 monthsInternational Physical Activity Questionnaire
Diet intakeDuring baseline week, after 4, 13, 30, and 50 weeks.3-day diet diaries (two weekdays and one weekend day) with online diet diary.
Sleep qualityFrom baseline to after 6 months and after 12 monthsThe Pittsburgh Sleep Quality Index questionnaire

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 14, 2026